Menu
← Oncology Approval Tracker
FDA DECISION ·
Ryzneuta
efbemalenograstim alfa-vuxw · Evive Biotechnology
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
To lower infection risk manifested by febrile neutropenia in adults with nonmyeloid malignancies receiving myelosuppressive cancer treatment with a clinically significant risk of febrile neutropenia.
LAMPGEN ANALYSIS
Why it matters
The approval added a long-acting G-CSF option for chemotherapy supportive care.
What research teams should watch
Document the chemotherapy regimen's febrile-neutropenia risk and coordinate post-chemotherapy administration.
PRIMARY RECORDS